Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Phoebe Starr

Authored Items
Targeted Therapy with Olaparib Beneficial in Metastatic Prostate Cancer with Gene Mutations
Phoebe Starr
Web Exclusives in ESMO
Ceritinib Effective in Treating Brain Metastases in NSCLC
Phoebe Starr
Web Exclusives in ESMO
Paradigm Shift: PARP Inhibitors Should Be Offered to All Patients with Ovarian Cancer
Phoebe Starr
Web Exclusives in ESMO
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
Phoebe Starr
Web Exclusives in Lung Cancer
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives in ESMO, Breast Cancer
FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs
Phoebe Starr
Web Exclusives in ASCO
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemo­immunotherapy in Relapsed/Refractory CLL
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 in ASH
Researchers Identify First Mutation to Explain Resistance to Venetoclax
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 in ASH
Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 in Immunotherapy, ASH
Durable Responses to CAR T-Cell Therapy in B-Cell Lymphomas
Phoebe Starr
JHOP - March 2019 Vol 9, No 1 in Lymphoma, ASH
Explosive Development of BCMA CAR T-Cell Therapy for Multiple Myeloma
Phoebe Starr
Web Exclusives in Immunotherapy, Multiple Myeloma
Brigatinib, Next-Generation ALK Inhibitor, Improves Survival versus Crizotinib in Patients with NSCLC and ALK Mutation
Phoebe Starr
Web Exclusives in Lung Cancer
5 mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer
Phoebe Starr
Web Exclusives in Breast Cancer
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
Phoebe Starr
Web Exclusives in Emerging Therapies
Nivolumab plus Ipilimumab Combo Controls Brain Metastases in Patients with Skin Cancer
Phoebe Starr
Web Exclusives in Immunotherapy
Less Is More: Six Months of Traxtuzumab Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
Web Exclusives in Breast Cancer
Immunotherapy Combinations “Raising the Bar”
Phoebe Starr
Web Exclusives in Immunotherapy
Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation
Phoebe Starr
Web Exclusives in Emerging Therapies
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
Web Exclusives in Immunotherapy
Obinutuzumab Prolongs Survival in Follicular Lymphoma
Phoebe Starr
Web Exclusives in Conference Correspondent, ASH
CAR T-Cell Therapy Succeeds in Aggressive Lymphoma
Phoebe Starr
Web Exclusives in Conference Correspondent, ASH
R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma
Phoebe Starr
Web Exclusives in Conference Correspondent, In the News
Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Phoebe Starr
Web Exclusives in Conference Correspondent, In the News
Last modified: June 18, 2020